China approves 21 children's medicines for market entry in 2021, with focus on enhancing child-specific policies.
China's National Medical Products Administration has approved 21 children's medicines for market entry in 2021, with a third prioritized for accelerated access. Since 2019, 271 children's drugs have been approved. The administration plans to enhance child-specific policies, protect related IP rights, and offer more tech guidance to R&D companies, ensuring safety and suitability for children during drug development.
June 01, 2024
6 Articles